Tevogen Inc. TVGN
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -66.22%
- 1 year
- -82.20%
- Open
- 5.99
- Prev close
- 5.90
- Mkt cap
- 87.97M
- Vol
- 5.99K
- Avg vol
- 8.41K
- EPS
- -6.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.59
- High
- 5.99
- Forward P/E
- 0.00
- Beta
- -1.03
- Short ratio
- 0.09
- Inst. own
- 3.82%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.49
- 200-d avg
- 1.37
- 1y target
- 4.20
News
2 weeks ago defenseworld.net
Tevogen Bio (NASDAQ:TVGN) Stock Falls 1.6% – Time to Sell?
Tevogen Bio Holdings Inc. (NASDAQ: TVGN - Get Free Report) shares dropped 1.6% during mid-day trading on Wednesday. The stock traded as low as $6.40 and last traded at $6.9990. 2,500 shares were…
3 weeks ago globenewswire.com
UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and…
-
3 weeks ago benzinga.com
Tevogen Signs Letter Of Intent To Evaluate A Potential Transaction With HRK Healthcare; Sees Path To Realizing ~$100M In Combined Annual Revenue
Tevogen Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and
3 weeks ago globenewswire.com
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and…
1 month ago globenewswire.com
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
WARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and…
-
3 months ago benzinga.com
Tevogen To Operate Under Tevogen Inc. Name, Effective July 30
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval by its Board of Directors. The name change…
3 months ago globenewswire.com
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval…
3 months ago globenewswire.com
Tevogen Bio Announces 2026 Annual Meeting of Stockholders
WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced that its 2026 Annual Meeting of Stockholders (the “Annual Meeting)” is…
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday's pre-market session. The company's market cap stands at $1.9 million. Decoy Therapeutics…
-
4 months ago benzinga.com
Tevogen Creates Healthcare Services Initiative Led By VP Of Strategic Initiatives William Keane On Interim Basis
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the formation of its healthcare services initiative, a strategic business area intended to support the Company's…
4 months ago globenewswire.com
Tevogen Announces Formation of a Healthcare Services Initiative
William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE)…
5 months ago globenewswire.com
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives…
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
5 months ago globenewswire.com
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter…
5 months ago globenewswire.com
Letter to Shareholders from CEO Dr. Ryan Saadi
Tevogen highlights improved operating performance, disciplined capital allocation, pipeline growth, and evaluation of revenue-generating acquisitions.
-
5 months ago benzinga.com
Tevogen Bio Holdings Q1 EPS $(1.61) Beats $(2.50) Estimate
Tevogen Bio Holdings (NASDAQ:TVGN) reported quarterly losses of $(1.61) per share which beat the analyst consensus estimate of $(2.50) by 35.6 percent. This is a 50.46 percent increase over losses of…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
5 months ago benzinga.com
Tevogen Enters $3M Private Placement PIPE Financing At $8.00/Prefunded Warrant, Issuing 375K Warrants Each Exercisable For The Purchase Of 1 Share Of The Company's Common Stock
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a securities purchase agreement for a private investment in public equity (the "PIPE")…
5 months ago globenewswire.com
Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private…
6 months ago globenewswire.com
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress within its artificial intelligence initiative,…
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
7 months ago benzinga.com
Tevogen Bio Eyes Acquisition Of Global CRO To Add $20M+ Revenue And Fuel Growth Across Oncology, Rare Diseases, And Medical Devices
Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates…
7 months ago globenewswire.com
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devices Target CRO operates…
-
7 months ago benzinga.com
Tevogen Bio Regains Nasdaq Compliance
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) received written notice (the "Notification Letter") from The Nasdaq Stock Market LLC notifying the Company that it had regained…
7 months ago globenewswire.com
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC…
7 months ago defenseworld.net
Tevogen Bio (TVGN) to Release Quarterly Earnings on Wednesday
Tevogen Bio (NASDAQ: TVGN - Get Free Report) will likely be releasing its results before the market opens on Wednesday, April 1st. Analysts expect Tevogen Bio to post earnings of ($0.0620) per share…
7 months ago globenewswire.com
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI,…
7 months ago globenewswire.com
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
Tevogen highlights capital discipline, minimal share use, strong insider ownership, and potential acquisitions while exploring ways to reflect asset value
-
7 months ago benzinga.com
Tevogen Reports Advanced Performance For Its AI Platform; Recent Testing Of PredicTcell Model Shows Recall Enhancement From 87% To 92%, Improved Precision From 40% To 48%
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI.Tevogen.AI was built to…
7 months ago globenewswire.com
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform,…
7 months ago globenewswire.com
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the company's…
7 months ago benzinga.com
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading…
-
7 months ago benzinga.com
Tevogen Names Leadership Team For Diversified Growth Strategy Targeting Additional $50M In Annual Revenue By Q2 2026 End
Leadership Designations:Digital Health: Arpita Patel and Wojtek StobinskiGenerics: Sadiq Khan and David BankoContract Research: William KeaneBiotech: Lori GrossoArtificial Intelligence: Mittul Mehta
7 months ago globenewswire.com
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the appointment of interim leaders across its core business…
8 months ago benzinga.com
Tevogen Bio Explores Buyout To Boost Generics Platform
Tevogen stock swings after Apozeal acquisition talks and a 50-for-1 reverse split as TVGN trades near lows.
8 months ago benzinga.com
Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday
Dow Jones falls 500 points on Friday, Marvell Technology shares jump 18.4%, other stocks recording gains include DAWN, BATL, RCAT, and SWBI.
-
8 months ago benzinga.com
Tevogen Bio Holdings Signs Letter Of Intent To Evaluate Potential Acquisition Of Apozeal Pharmaceutical
If consummated, the potential acquisition of Apozeal could provide Tevogen with an established generics platform, including:11 FDA-approved Abbreviated New Drug Application (ANDA) products for the…
-
8 months ago benzinga.com
UPDATE: Tevogen Bio Holdings Approves 1-For-50 Reverse Stock Split Effective March 6, 2026
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its Board of Directors (the "Board") has approved a reverse stock split of its common stock at a ratio of 50 for…
-
8 months ago benzinga.com
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Lowers Price Target to $2
D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy and lowers the price target from $5 to $2.
-
8 months ago benzinga.com
Tevogen Strikes Letter Of Intent To Mull Potential Takeover Of Unnamed Contract Research Organization
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent ("LoI") to evaluate a potential…
-
8 months ago benzinga.com
Tevogen Signs Non-Exclusive, Non-Binding LOI To Evaluate Potential Transaction With Sciometrix To Augment Capabilities And Transition Into Revenue‑Generating Healthcare Enterprise
Tevogen ("Tevogen Bio Holdings Inc.") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent ("LoI") to evaluate a potential transaction with…
-
9 months ago benzinga.com
Tevogen Evaluates Potential One-Time Special Cash Dividend, Subject To Future Financial Milestones
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special…
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
9 months ago benzinga.com
Tevogen Reports 2025 Milestones, Expands ExacTcell Platform And Multi-Indication CTL Pipeline; Advances In-House GMP Manufacturing Capabilities
Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare ConferenceWARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today…
-
9 months ago benzinga.com
Tevogen Provided Updates At J.P. Morgan Healthcare Conference
Pipeline Expansion Across Multiple Indications:Building on its SARS-CoV-2 proof-of-concept clinical experience, Tevogen completed T cell target identification for five additional HLA restrictions,…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
11 months ago benzinga.com
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
-
11 months ago benzinga.com
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Lowers Price Target to $5
D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy and lowers the price target from $10 to $5.